Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

Abstract Background Locally advanced or metastatic adenocarcinoma of the pancreas remains - despite the implementation of new chemotherapy protocols - a disease with short overall survival (OS). Methods Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the panc...

Full description

Bibliographic Details
Main Authors: Ursula M. Vogl, Haleh Andalibi, Alexander Klaus, Laurenz Vormittag, Wolfgang Schima, Bettina Heinrich, Alice Kafka, Thomas Winkler, Leopold Öhler
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
FOLFIRINOX
Nab-paclitaxel
Gemcitabine
Online Access:http://link.springer.com/article/10.1186/s12885-018-5240-6

Internet

http://link.springer.com/article/10.1186/s12885-018-5240-6

Similar Items